Top

Published in:

Open Access 01-12-2019 | Expectoration | Case report

Impact of clonally-related Burkholderia contaminans strains in two patients attending an Italian cystic fibrosis centre: a case report

Authors: Daniela Savi, Serena Quattrucci, Maria Trancassini, Claudia Dalmastri, Riccardo V. De Biase, Marta Maggisano, Paolo Palange, Annamaria Bevivino

Published in: BMC Pulmonary Medicine | Issue 1/2019

Abstract

Background

Burkholderia contaminans is one of the 20 closely related bacterial of the Burkholderia cepacia complex, a group of bacteria that are ubiquitous in the environment and capable of infecting people with cystic fibrosis (CF). This species is an emerging pathogen and it has been widely isolated from CF patients in Argentina, Spain, Portugal, Australia, Canada, USA with a low prevalence in Ireland, France, Russia, Switzerland, Czech Republic, and Italy. This is the first report of B. contaminans affecting two Italian CF patients attending the same CF Centre. We correlate B. contaminans colonisation with lung function decline and co-infection with other clinically relevant CF pathogens.

Case presentation

B. contaminans was identified by Multi Locus Sequence Typing in routine sputum analysis of two Caucasian CF women homozygous for Phe508del CFTR mutation. Sequence Type 102 was detected in both strains. It is known that B. contaminans ST102 was isolated both from CF and non-CF patients, with an intercontinental spread across the world. Random Amplified Polymorphic DNA analysis revealed the genetic relatedness between the two strains. We examined their susceptibility to antimicrobial agents, comparing the latter with that recorded for other B. contaminans isolated from different countries. We also described key virulence factors possibly linked with a clinical outcome. Specifically, we attempted to correlate colonization with the incidence of acute exacerbation of symptoms and lung function decline.

Conclusions

This case presentation suggests that acquisition of B. contaminans ST102 is not directly associated with a lung function decline. We retain that the presence of other CF pathogens (i.e. MRSA and Trichosporon) along with B. contaminans ST102 might have contributed to the worsening of clinical conditions in our CF patients. The circumstances leading to the establishment of B. contaminans ST102 infections are still unknown. We highlight the importance to proper detect and typing bacteria implicated in CF infection by using molecular techniques.

Mahenthiralingam E, Urban TA, Goldberg JB. The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Microbiol. 2005;3:144–56.CrossRef

Courtney JM, Dunbar KE, McDowell A, Moore JE, Warke TJ, Stevenson M, et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros. 2004;3:93–8.CrossRef

Rhodes KA, Schweizer HP. Antibiotic resistance in Burkholderia species. Drug Resist Updat. 2016;28:82–90.CrossRef

Lucarelli M, Porcaro L, Biffignandi A, Costantino L, Giannone V, Alberti L, et al. A new targeted CFTR mutation panel based on next-generation sequencing technology. J Mol Diagn. 2017;19(5):788–800. https://doi.org/10.1016/j.jmoldx.2017.06.002.CrossRefPubMed

Baldwin A, Mahenthiralingam E, Thickett KM, Honeybourne D, Maiden MC, Govan JR, et al. Multilocus sequence typing scheme that provides both species and strain differentiation for the Burkholderia cepacia complex. J Clin Microbiol. 2005;43:4665–73. https://doi.org/10.1128/JCM.43.9.4665-4673.2005.CrossRefPubMedPubMedCentral

Mahenthiralingam E, Coenye T, Chung JW, Speert DP, Govan JR, Taylor P, et al. Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex. J Clin Microbiol. 2000;38:910–3.PubMedPubMedCentral

Vermis K, Coenye T, Lipuma JJ, Mahenthiralingam E, Nelis HJ, Vandamme P. Proposal to accommodate Burkholderia cepacia genomovar VI as Burkholderia dolosa sp. nov. Int J Syst Evol Microbiol. 2004;54:689–91. https://doi.org/10.1099/ijs.0.02888-0.CrossRefPubMed

Vanlaere E, Lipuma JJ, Baldwin A, Henry D, de Brandt E, Mahenthiralingam E, et al. Burkholderia latens sp. nov., Burkholderia diffusa sp. nov., Burkholderia arboris sp. nov., Burkholderia seminalis sp. nov. and Burkholderia metallica sp. nov., novel species within the Burkholderia cepacia complex. Int J Syst Evol Microbiol. 2008;58:1580–90. https://doi.org/10.1099/ijs.0.65634-0.CrossRefPubMed

Vanlaere E, Baldwin A, Gevers D, Henry D, de Brandt E, LiPuma JJ, et al. Taxon K, a complex within the Burkholderia cepacia complex, comprises at least two novel species, Burkholderia contaminans sp. nov. and Burkholderia lata sp. nov. Int J Syst Evol Microbiol. 2009;59:102–11. https://doi.org/10.1099/ijs.0.001123-0.CrossRefPubMed

10.

Peeters C, Zlosnik JE, Spilker T, Hird TJ, Lipuma JJ, Vandamme P. Burkholderia pseudomultivorans sp. nov., a novel Burkholderia cepacia complex species from human respiratory samples and the rhizosphere. Syst Appl Microbiol. 2013;36:483–9. https://doi.org/10.1016/j.syapm.2013.06.003.CrossRefPubMed

11.

de Smet B, Mayo M, Peeters C, Zlosnik JE, Spilker T, Hird TJ, et al. Burkholderia stagnalis sp. nov. and Burkholderia territorii sp. nov., two novel Burkholderia cepacia complex species from environmental and human sources. Int J Syst Evol Microbiol. 2015;65:2265–71. https://doi.org/10.1099/ijs.0.000251.CrossRefPubMed

12.

Drevinek P, Mahenthiralingam E. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. Clin Microbiol Infect. 2010;16(7):821–30. https://doi.org/10.1111/j.1469-0691.2010.03237.x.CrossRefPubMed

13.

Zahariadis G, Levy MH, Burns JL. Cepacia-like syndrome caused by Burkholderia multivorans. Can J Infect Dis. 2003;14(2):123–5. https://doi.org/10.1155/2003/675159.CrossRefPubMedPubMedCentral

14.

Shafiq I, Carroll MP, Nightingale JA, Daniels TVW. Cepacia syndrome in a cystic fibrosis patient colonised with Burkholderia multivorans. BMJ Case Rep. 2011. https://doi.org/10.1136/bcr.08.2010.3296.

15.

Blackburn L, Brownlee K, Conway S, Denton M. “Cepacia syndrome” with Burkholderia multivorans, 9 years after initial colonization. J Cyst Fibros. 2004;3:133–4. https://doi.org/10.1016/j.jcf.2004.03.007.CrossRefPubMed

16.

Kalish LA, Waltz DA, Dovey M, PotteryBynoe G, McAdam AJ, LiPuma JJ, et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med. 2006;173:421–5. https://doi.org/10.1164/rccm.200503-344OC.CrossRefPubMed

17.

Venter JC, Remington K, Heidelberg JF, et al. Environmental genome shotgun sequencing of the sargasso sea. Science. 2004;304:66–74.CrossRef

18.

Martin M, Christiansen B, Caspari G, Hogardt M, von Thomsen AJ, Ott E, et al. Hospital-wide outbreak of Burkholderia contaminans caused by prefabricated moist washcloths. J Hosp Infect. 2011;77(3):267–70. https://doi.org/10.1016/j.jhin.2010.10.004.CrossRefPubMed

19.

Moehring RW, Lewis SS, Isaacs PJ, Schell WA, Thomann WR, Althaus MM, et al. Outbreak of bacteremia due to Burkholderia contaminans linked to intravenous fentanyl from an institutional compounding pharmacy. JAMA Intern Med. 2014;174(4):606–12. https://doi.org/10.1001/jamainternmed.2013.13768.CrossRefPubMed

20.

Bloodworth RA, Selin C, Lopez De Volder MA, Drevinek P, Galanternik L, Degrossi J, et al. Draft genome sequences of Burkholderia contaminans, a Burkholderia cepacia complex species that is increasingly recovered from cystic fibrosis patients. Genome Announc. 2015;3(4):e00766–15. https://doi.org/10.1128/genomeA.00766-15.CrossRefPubMedPubMedCentral

21.

Ohji G, Ohkusu K, Toguchi A, Otsuka Y, Hosokawa N, Iwata K. Burkholderia contaminans: unusual cause of biliary sepsis. J Infect Chemother. 2013;19(5):969–71.CrossRef

22.

Peterson AE, Chitnis AS, Xiang N, Scaletta JM, Geist R, Schwartz J, et al. Clonally related Burkholderia contaminans among ventilated patients without cystic fibrosis. Am J Infect Control. 2013;41(12):1298–300. https://doi.org/10.1016/j.ajic.2013.05.015.CrossRefPubMedPubMedCentral

23.

Medina-Pascual MJ, Valdezate S, Carrasco G, Villalón P, Garrido N, Saéz-Nieto JA. Increase in isolation of Burkholderia contaminans from Spanish patients with cystic fibrosis. Clin Microbiol Infect. 2015;21(2):150–6. https://doi.org/10.1016/j.cmi.2014.07.014.CrossRefPubMed

24.

Martina P, Bettiol M, Vescina C, Montanaro P, Mannino MC, Prieto CI, et al. Genetic diversity of Burkholderia contaminans isolates from cystic fibrosis patients in Argentina. J Clin Microbiol. 2013;51(1):339–44. https://doi.org/10.1128/JCM.02500-12.CrossRefPubMedPubMedCentral

25.

Mahenthiralingam E, Baldwin A, Drevinek P, Vanlaere E, Vandamme P, et al. Multilocus sequence typing breathes life into a microbial metagenome. PLoS One. 2006;1(1):e17. https://doi.org/10.1371/journal.pone.0000017.CrossRefPubMedPubMedCentral

26.

Smyth AR, Scott C, Bojcind S, Bryone M, Duff A, Flume P, et al. European cystic fibrosis society standards of care: best practice guidelines. J Cyst Fibros. 2014;13(Suppl. 1):S23–42.CrossRef

27.

Giovannetti L, Ventura S, Bazzicalupo M, Fani R, Materassi R. DNA restriction fingerprint analysis of the soil bacterium Azospirillum. J Gen Microbiol. 1990;136:1161–6. https://doi.org/10.1099/00221287-136-6-1161.CrossRefPubMed

28.

Cesarini S, Bevivino A, Tabacchioni S, Chiarini L, Dalmastri C. RecA gene sequence and multilocus sequence typing for species-level resolution of Burkholderia cepacia complex isolates. Lett Appl Microbiol. 2009;49:580–8. https://doi.org/10.1111/j.1472-765X.2009.02709.CrossRefPubMed

29.

Jolley KA, Chan MS, Maiden MC. mlstdbNet - distributed multi-locus sequence typing (MLST) databases. BMC Bioinf. 2004;5:86. https://doi.org/10.1186/1471-2105-5-86.CrossRef

30.

Mahenthiralingam E, Simpson DA, Speert DP. Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis. J Clin Microbiol. 1997;35:808–16.PubMedPubMedCentral

31.

Clinical and Laboratory Standards Institute (CLSI) Performance standards for Antimicrobial Susceptibility Testing; Sixteen Informational supplement. 26 3:2006.

32.

Mahenthiralingam E, Baldwin A, Dowson CG. Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology. J Appl Microbiol. 2008;104:1539–51. https://doi.org/10.1111/j.1365-2672.2007.03706.CrossRefPubMed

33.

Kenna DTD, Lilley D, Coward A, Martin K, Perry C, Pike R, et al. Prevalence of Burkholderia species, including members of Burkholderia cepacia complex, among UK cystic and non-cystic fibrosis patients. J Med Microbiol. 2017;66:490–501. https://doi.org/10.1099/jmm.0.000458.CrossRefPubMed

34.

Berriatua E, Ziluaga I, Miguel-Virto C, Uribarren P, Juste R, Laevens S, et al. Outbreak of subclinical mastitis in a flock of dairy sheep associated with Burkholderia cepacia complex infection. J Clin Microbiol 2001;39:990–994. doi: https://doi.org/10.1128/JCM.39.3.990-994.2001.

35.

Souza AV, Moreira CR, Pasternak J, Hirata Mde L, Saltini DA, Caetano VC, et al. Characterizing uncommon Burkholderia cepacia complex isolates from an outbreak in a haemodialysis unit. J Med Microbiol. 2004;53:999–1005. https://doi.org/10.1099/jmm.0.45702-0.CrossRefPubMed

36.

Campana S, Taccetti G, Ravenni N, Favari F, Cariani L, Sciacca A, et al. Transmission of Burkholderia cepacia complex: evidence for new epidemic clones infecting cystic fibrosis patients in Italy. J Clin Microbiol. 2005;43:5136–42. https://doi.org/10.1128/JCM.43.10.5136-5142.2005.CrossRefPubMedPubMedCentral

37.

Cunha MV, Pinto-de-Oliveira A, Meirinhos-Soares L, Salgado MJ, Melo-Cristino J, et al. Exceptionally high representation of Burkholderia cepacia among B. cepacia complex isolates recovered from the major Portuguese cystic fibrosis center. J Clin Microbiol. 2007;45:1628–33. https://doi.org/10.1128/JCM.00234-07.CrossRefPubMedPubMedCentral

38.

Vanlaere E, Coenye T, Samyn E, Van den Plas C, Govan J, De Baets F, et al. A novel strategy for the isolation and identification of environmental Burkholderia cepacia complex bacteria. FEMS Microbiol Lett. 2005;249:303–7. https://doi.org/10.1016/j.femsle.2005.06.026.CrossRefPubMed

39.

Martina P, Feliziani S, Juan C, Bettiol M, Gatti B, Yantorno O, et al. Hypermutation in Burkholderia cepacia complex is mediated by DNA mismatch repair inactivation and is highly prevalent in cystic fibrosis chronic respiratory infection. Int J of Med Microbiol. 2014;304(8):1182–91. https://doi.org/10.1016/j.ijmm.2014.08.011.CrossRef

40.

Nunvar J, Kalferstova L, Bloodworth RAM, Kolar M, Degrossi J, Lubovich S, et al. Understanding the Pathogenicity of Burkholderia contaminans, an Emerging Pathogen in Cystic Fibrosis. PLOS ONE. 2016;11(8). https://doi.org/10.1371/journal.pone.0160975.

41.

Coutinho CP, Barreto C, Pereira L, Lito L, Melo Cristino J, Sá-Correia I. Incidence of Burkholderia contaminans at a cystic fibrosis center with an unusually high representation of Burkholderia cepacia during 15 years of epidemiological surveillance. J Med Microbiol. 2015;64:927–35. https://doi.org/10.1099/jmm.0.000094.CrossRefPubMed

42.

Esther CR Jr, Plongla R, Kerr A, Lin FC, Gilligan P. Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection. J Cyst Fibros. 2016;15(5):e45–9. https://doi.org/10.1016/j.jcf.2016.02.006.CrossRefPubMed

Title: Impact of clonally-related Burkholderia contaminans strains in two patients attending an Italian cystic fibrosis centre: a case report
Authors: Daniela Savi
Serena Quattrucci
Maria Trancassini
Claudia Dalmastri
Riccardo V. De Biase
Marta Maggisano
Paolo Palange
Annamaria Bevivino
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Expectoration
Cystic Fibrosis
Tobramycin
Cystic Fibrosis
Published in: BMC Pulmonary Medicine / Issue 1/2019
Electronic ISSN: 1471-2466
DOI: https://doi.org/10.1186/s12890-019-0923-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Impact of clonally-related Burkholderia contaminans strains in two patients attending an Italian cystic fibrosis centre: a case report

Abstract

Background

Case presentation

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Ursolic acid alleviates airway-vessel remodeling and muscle consumption in cigarette smoke-induced emphysema rats

Patients with overlapping diagnoses of asthma and COPD: is livestock exposure a risk factor for comorbidity and coexisting symptoms and infections?

Circulating tumor cells prior to initial treatment is an important prognostic factor of survival in non-small cell lung cancer: a meta-analysis and system review

The predictive value of diaphragm ultrasound for weaning outcomes in critically ill children

The role of secreted Hsp90α in HDM-induced asthmatic airway epithelial barrier dysfunction

Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page